Navigation Links
Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
Date:9/8/2008

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Takeda San Francisco Inc. announced today that Gregory Landes, Ph.D., has joined the company as vice president of antibody research. Dr. Landes will be responsible for directing the discovery and preclinical development of therapeutic antibodies at Takeda's antibody IND engine and center of excellence for biologics.

"Greg brings over 25 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D. president and chief scientific officer, Takeda San Francisco. "Greg's extensive experience covers key aspects of antibody drug discovery and development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of advancing superior therapeutics to contribute to the health of individuals."

Dr. Landes previously has held executive positions with major biopharmaceutical companies, including Lexicon Pharmaceuticals, Abgenix, Inc. and Genzyme Corp, where he led antibody drug discovery, antibody development and functional genomics. He has authored more than 49 peer-reviewed publications and is co-inventor on 12 issued plus additional pending patents. He holds a BA in Chemistry and PhD in Biochemistry from the University of Kansas and was a post-doctoral scholar at UCLA.

About Takeda San Francisco

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and development of antibodies, enhancement of antibody activity and antibody-manufacturing in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.


'/>"/>
SOURCE Takeda San Francisco Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
2. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
3. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
4. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
5. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
6. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
7. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... market news outlet had provided a research update on Aytu Bioscience and cited ... product. , According to Soulstring, prescription rates for Natesto® have more than doubled ...
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):